NYSE - Delayed Quote • USD
CONMED Corporation (CNMD)
At close: April 24 at 4:00 PM EDT
Pre-Market: 8:00 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 8 |
| Avg. Estimate | 0.97 | 1.19 | 4.33 | 5.62 |
| Low Estimate | 0.94 | 1.14 | 4.3 | 5.37 |
| High Estimate | 1.11 | 1.26 | 4.36 | 5.8 |
| Year Ago EPS | 0.83 | 0.9 | 3.45 | 4.33 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 8 |
| Avg. Estimate | 341.9M | 337.94M | 1.35B | 1.52B |
| Low Estimate | 338.38M | 333.7M | 1.34B | 1.44B |
| High Estimate | 350.65M | 346.8M | 1.36B | 1.9B |
| Year Ago Sales | 306.09M | 304.58M | 1.24B | 1.35B |
| Sales Growth (year/est) | 11.70% | 11.00% | 8.40% | 12.70% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.79 | 0.83 | 1.11 | 0.74 |
| EPS Actual | 0.83 | 0.9 | 1.06 | 0.79 |
| Difference | 0.04 | 0.07 | -0.05 | 0.05 |
| Surprise % | 5.10% | 8.40% | -4.50% | 6.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.97 | 1.19 | 4.33 | 5.62 |
| 7 Days Ago | 0.97 | 1.19 | 4.33 | 5.62 |
| 30 Days Ago | 0.97 | 1.19 | 4.33 | 5.62 |
| 60 Days Ago | 0.99 | 1.18 | 4.33 | 5.62 |
| 90 Days Ago | 1.08 | 1.1 | 4.4 | 5.82 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CNMD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 16.90% | -- | -- | 1.50% |
| Next Qtr. | 32.20% | -- | -- | 11.40% |
| Current Year | 25.50% | -- | -- | 5.20% |
| Next Year | 29.80% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 25.40% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 4.97% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Needham: Buy to Buy | 4/25/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 2/1/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 2/1/2024 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 2/1/2024 |
| Maintains | Needham: Buy to Buy | 2/1/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 10/27/2023 |
Related Tickers
IART Integra LifeSciences Holdings Corporation
29.38
0.00%
PEN Penumbra, Inc.
206.15
+0.22%
STE STERIS plc
202.80
-1.55%
IRTC iRhythm Technologies, Inc.
116.43
+0.08%
NVRO Nevro Corp.
12.51
-2.19%
NARI Inari Medical, Inc.
38.18
+2.88%
TMCI Treace Medical Concepts, Inc.
10.67
-1.75%
SNN Smith & Nephew plc
24.57
-0.93%
ATEC Alphatec Holdings, Inc.
12.74
-1.47%
CVRX CVRx, Inc.
14.40
+0.77%